Commercial Post-marketing oncology studies: Enabling faster recruitment and lower costs Pharmaceutical TechnologyIn clinical trials, post-marketing approval studies remain a lower priority than other research areas, especially at community oncology centers.OncologyRead full story pharminent June 22, 2026 (Last updated: June 22, 2026) Pharmaceutical Technology In clinical trials, post-marketing approval studies remain a lower priority than other research areas, especially at community oncology centers. Oncology Read full story Post navigation Previous: Sun Pharma to acquire Innovcare Lifesciences for $28.7mNext: Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance Related Stories Commercial Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand pharminent September 14, 2026 Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026